Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | NEJM
Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)–based expression of factor …